NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 137 filers reported holding NEKTAR THERAPEUTICS in Q3 2023. The put-call ratio across all filers is 5.78 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $7,403 | +5.1% | 12,429 | +1.5% | 0.00% | – |
| Q2 2023 | $7,043 | -74.7% | 12,244 | -69.1% | 0.00% | – |
| Q1 2023 | $27,838 | -72.2% | 39,605 | -10.7% | 0.00% | – |
| Q4 2022 | $100,288 | -22.9% | 44,375 | +8.6% | 0.00% | – |
| Q3 2022 | $130,000 | -21.2% | 40,869 | -5.6% | 0.00% | -100.0% |
| Q2 2022 | $165,000 | +2.5% | 43,288 | +45.5% | 0.00% | – |
| Q1 2022 | $161,000 | -67.3% | 29,749 | -18.3% | 0.00% | -100.0% |
| Q4 2021 | $492,000 | -51.3% | 36,405 | -35.3% | 0.00% | -66.7% |
| Q3 2021 | $1,011,000 | +11.0% | 56,303 | +6.0% | 0.00% | 0.0% |
| Q2 2021 | $911,000 | +6.8% | 53,117 | +24.6% | 0.00% | 0.0% |
| Q1 2021 | $853,000 | +11.6% | 42,639 | -5.2% | 0.00% | 0.0% |
| Q4 2020 | $764,000 | +4.7% | 44,957 | +2.2% | 0.00% | 0.0% |
| Q3 2020 | $730,000 | -26.9% | 43,995 | +2.1% | 0.00% | -40.0% |
| Q2 2020 | $998,000 | +65.0% | 43,087 | +27.0% | 0.01% | +25.0% |
| Q1 2020 | $605,000 | -51.0% | 33,920 | -40.6% | 0.00% | -33.3% |
| Q4 2019 | $1,234,000 | -5.8% | 57,152 | -20.5% | 0.01% | -14.3% |
| Q3 2019 | $1,310,000 | -50.0% | 71,894 | -2.4% | 0.01% | -56.2% |
| Q2 2019 | $2,622,000 | -19.6% | 73,689 | -24.1% | 0.02% | -20.0% |
| Q1 2019 | $3,260,000 | -33.2% | 97,024 | -34.7% | 0.02% | -41.2% |
| Q4 2018 | $4,882,000 | -42.6% | 148,516 | +6.5% | 0.03% | -41.4% |
| Q3 2018 | $8,500,000 | +53.5% | 139,442 | +23.0% | 0.06% | +56.8% |
| Q2 2018 | $5,538,000 | -56.0% | 113,412 | -4.2% | 0.04% | -54.9% |
| Q1 2018 | $12,575,000 | +81.7% | 118,343 | +2.1% | 0.08% | +70.8% |
| Q4 2017 | $6,920,000 | +174.6% | 115,875 | +10.3% | 0.05% | +108.7% |
| Q3 2017 | $2,520,000 | +35.6% | 105,011 | +10.5% | 0.02% | +21.1% |
| Q2 2017 | $1,858,000 | -22.0% | 95,049 | -6.4% | 0.02% | -24.0% |
| Q1 2017 | $2,383,000 | +52.7% | 101,533 | -20.2% | 0.02% | +47.1% |
| Q4 2016 | $1,561,000 | -12.2% | 127,226 | +23.0% | 0.02% | -32.0% |
| Q3 2016 | $1,778,000 | +3.9% | 103,470 | -14.0% | 0.02% | +13.6% |
| Q2 2016 | $1,712,000 | +5.5% | 120,322 | +2.0% | 0.02% | 0.0% |
| Q1 2016 | $1,622,000 | -25.8% | 117,986 | -9.1% | 0.02% | -15.4% |
| Q4 2015 | $2,187,000 | +72.1% | 129,779 | +11.9% | 0.03% | +44.4% |
| Q3 2015 | $1,271,000 | -18.1% | 115,981 | -6.5% | 0.02% | -14.3% |
| Q2 2015 | $1,552,000 | +8.2% | 124,078 | -4.8% | 0.02% | +23.5% |
| Q1 2015 | $1,434,000 | -17.4% | 130,385 | +16.3% | 0.02% | -15.0% |
| Q4 2014 | $1,737,000 | +24.3% | 112,093 | -3.2% | 0.02% | +5.3% |
| Q3 2014 | $1,397,000 | -24.1% | 115,781 | -19.3% | 0.02% | -20.8% |
| Q2 2014 | $1,840,000 | -33.4% | 143,538 | -37.0% | 0.02% | -31.4% |
| Q1 2014 | $2,763,000 | +284.3% | 227,962 | +259.9% | 0.04% | +218.2% |
| Q4 2013 | $719,000 | -41.1% | 63,339 | -45.8% | 0.01% | -62.1% |
| Q3 2013 | $1,220,000 | +6.5% | 116,769 | +17.7% | 0.03% | +31.8% |
| Q2 2013 | $1,146,000 | – | 99,185 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Camber Capital Management LP | 3,500,000 | $60,060,000 | 2.02% |
| ACT CAPITAL MANAGEMENT, LLC | 161,500 | $2,772,000 | 1.42% |
| Rhenman & Partners Asset Management AB | 950,000 | $16,302,000 | 1.11% |
| MAVERICK CAPITAL LTD | 5,761,073 | $98,860,000 | 0.93% |
| Birchview Capital, LP | 72,000 | $1,236,000 | 0.74% |
| Bellevue Group AG | 4,101,404 | $70,380,000 | 0.69% |
| CM Management, LLC | 50,000 | $858,000 | 0.62% |
| Duquesne Family Office | 1,000,000 | $17,160,000 | 0.42% |
| OSTERWEIS CAPITAL MANAGEMENT INC | 373,368 | $6,407,000 | 0.33% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 67,000 | $1,149,000 | 0.30% |